Genmab receives fda breakthrough therapy designation for rinatabart sesutecan (rina-s®) in advanced endometrial cancer (ec)

Copenhagen, denmark--(business wire)--genmab a/s (nasdaq: gmab) announced today that the u.s. food and drug administration (fda) has granted breakthrough therapy designation (btd) to rinatabart sesutecan (rina-s®), an investigational folate receptor alpha (frΑ)-directed, topo1-inhibitor antibody-drug conjugate (adc), for the treatment of adult patients with recurrent or progressive endometrial cancer (ec) who have disease progression on or following prior treatment with a platinum-containing re.
EC Ratings Summary
EC Quant Ranking